Genome Publications
https://doi.org/10.61096/ 978-81-981372-8-9_4

Chapter 4

Herbal Formulations For Immune Support In Liver Disease

Dr. Joysa Ruby Joseph
Department of Pharmaceutics, Acharya & BM Reddy College of Pharmacy,
Bangalore, Karnataka, India.
Ms. Thamaraikavi Kasinathan
Department of Pharmacognosy, Sir Issac Newton College of Pharmacy,
Nagapattinam, Tamilnadu, India.
Mrs. Manju Subramanian
Department of Pharmaceutics, Cherraans College of Pharmacy,
Coimbatore, Tamilnadu, India.
Mr. Sivaneshwar Shanmugadurai
Department of Pharmaceutics, Cherraans College of Pharmacy,
Coimbatore, Tamilnadu, India.

Abstract: Liver diseases significantly impact global health, often leading to immune dysregulation, chronic inflammation, and increased susceptibility to infections. The liver plays a crucial role in modulating immune responses, but chronic conditions such as cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) can compromise its immunological function. Herbal formulations have long been used in traditional medicine systems, including Ayurveda and Traditional Chinese Medicine (TCM), to support liver function and immune health. Modern research validates the immunomodulatory, anti-inflammatory, and antioxidant properties of various herbs, including Milk Thistle, Turmeric, Licorice, Schisandra, and Astragalus. These botanicals act through multiple pathways, such as reducing oxidative stress, regulating cytokine balance, and enhancing hepatic detoxification. Advances in herbal formulation technology, including phytosomes, nanoemulsions, and liposomal delivery, have improved bioavailability and efficacy. This chapter explores the pathophysiology of immune dysfunction in liver disease, the role of herbal medicine in restoring immune balance, and the integration of traditional knowledge with modern scientific advancements. While herbal formulations hold promise, challenges such as standardization, herb-drug interactions, and regulatory frameworks must be addressed to ensure safe and effective clinical applications.

Keywords: Liver disease, immune modulation, herbal medicine, antioxidants, inflammation, Milk Thistle, Turmeric, Licorice, Schisandra, phytotherapy, hepatoprotection, traditional medicine, integrative healthcare.

Citation: Joysa Ruby Joseph, Thamaraikavi Kasinathan, Manju Subramanian, Sivaneshwar Shanmugadurai. Herbal Formulations For Immune Support In Liver Disease. *Advancements in Hepatoprotective Herbal Medicines Current Trends, Significance, and Future Perspectives.* Genome Publications. 2025; Pp46-55. https://doi.org/10.61096/978-81-981372-8-9_4

INTRODUCTION

Liver diseases are a significant global health burden, contributing to high morbidity and mortality rates [1,2]. The primary functions of the liver include detoxification, biosynthesis of essential proteins, and regulation of metabolic homeostasis[3]. However, the liver also has an extraordinary capacity to modulate immune responses through resident immune cells such as Kupffer cells and hepatic dendritic cells [4]. Chronic liver disease can impair this immunological function and exacerbate systemic inflammation, leading to complications like fibrosis, cirrhosis, and increased susceptibility to infections [5]. Herbal formulations have been used for centuries in traditional medical systems, such as Ayurveda and Traditional Chinese Medicine (TCM), to improve liver function and overall health [6,7]. In modern times, research has increasingly focused on validating these traditional claims through in vitro, in vivo, and clinical studies[8,9]. Herbs are complex matrices containing multiple bioactive phytochemicals—such as flavonoids, phenolic acids, lignans, saponins, and alkaloids—that act on different molecular pathways[10]. This polypharmacological nature may offer advantages over single-compound drugs, potentially reducing adverse effects while enhancing therapeutic efficacy[11]. In this chapter, we review the pathophysiology of immune dysfunction in liver disease and elucidate how herbal formulations can address immune dysregulation. We also discuss the underlying mechanisms, formulation approaches, safety considerations, and challenges. The chapter concludes with future directions, emphasizing the need for integrative and personalized therapies, as well as the importance of robust clinical research to establish best practices.

LIVER DISEASE AND IMMUNE DYSREGULATION

Mechanisms of Immune Dysfunction

The liver is central to maintaining immune tolerance, filtering pathogens and toxins from the bloodstream, and orchestrating both innate and adaptive immunity[12]. Chronic liver injury—due to viral infections (hepatitis B and C), toxins (alcohol, environmental chemicals), metabolic disorders (non-alcoholic fatty liver disease [NAFLD]), or autoimmune processes—triggers persistent inflammation[13]. This sustained inflammatory milieu disrupts the balance of pro- and anti-inflammatory cytokines, leading to immune dysregulation[14]. Key drivers include:

- **Cytokine Imbalance**: Elevated levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) perpetuate chronic inflammation[15].
- **Oxidative Stress**: Overproduction of reactive oxygen species (ROS) damages hepatocytes and further stimulates pro-inflammatory pathways[16].
- **Gut–Liver Axis**: Increased intestinal permeability (“leaky gut”) allows microbial products to enter the portal circulation, activating immune cells in the liver and aggravating hepatic inflammation[17].

Clinical Implications

Unchecked hepatic inflammation can lead to fibrosis, cirrhosis, and portal hypertension, significantly raising the risk of hepatocellular carcinoma (HCC)[18]. Patients with advanced cirrhosis often experience immune suppression, leaving them vulnerable to opportunistic infections, spontaneous bacterial peritonitis, and sepsis [19]. Autoimmune liver diseases, such as autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), further exemplify how dysregulated immune pathways can directly target liver tissue[20].

Rationale for Targeting Immunity in Liver Disease Management

Conventional treatments for chronic liver diseases often address viral eradication (e.g., antivirals for hepatitis B and C), lifestyle modifications (e.g., weight reduction in NAFLD), or immunosuppression (in autoimmune conditions)[21]. While these approaches are valuable, adjunctive strategies that modulate the immune system can further mitigate inflammation, slow disease progression, and potentially reduce adverse effects of standard therapies[22].

PRINCIPLES OF HERBAL MEDICINE IN LIVER HEALTH

Phytochemical Foundations

Herbal medicines comprise diverse bioactive compounds that may provide synergistic therapeutic effects[23]. Key phytochemical categories include:

- **Polyphenols (Flavonoids, Phenolic Acids)**: Potent antioxidants that scavenge ROS and modulate signaling pathways to reduce inflammation[24].
- **Lignans**: Known for hepatoprotective properties, such as silymarin from milk thistle[25].
- **Saponins**: Found in various herbs, these compounds can stabilize cell membranes and exhibit immunomodulatory activities[26].
- **Alkaloids and Terpenes**: Often show anti-inflammatory, antiviral, or adaptogenic properties[27].

Traditional Perspectives

Ayurvedic Medicine views the liver as a key organ in balancing Pitta (metabolic fire) and overall detoxification. Preparations often incorporate bitter herbs to cool the liver and reduce inflammation[28]. Traditional Chinese Medicine (TCM) emphasizes the Liver Meridian and the concept of preserving Qi flow. Herbs that "soothe the Liver" and "resolve stagnation" are integral to TCM formulations[29].

Modern Integrative Approach

Contemporary practice blends ancient wisdom with scientific validation. Standardized herbal extracts are now commonly used, guaranteeing consistent levels of marker compounds and facilitating dose determination[30]. Additionally, advanced analytical tools (e.g., high-performance liquid chromatography) confirm the identity and purity of herbal products, improving both safety and efficacy [31].

Mechanisms of Action of Herbal Formulations

Antioxidant and Anti-Inflammatory Properties

Oxidative stress and chronic inflammation serve as key pathophysiological drivers in most liver diseases[32]. Herbal formulations often contain compounds that target oxidative pathways by:

- **Scavenging ROS**: Reducing cellular damage and maintaining redox balance [33].
- **Upregulating Endogenous Antioxidants**: Enhancing glutathione (GSH), superoxide dismutase (SOD), and catalase activities [34].
- **Inhibiting NF-κB Signaling**: NF-κB regulates inflammatory cytokine production; many herbal constituents downregulate this pathway [35].

Immunomodulatory Pathways

Several herbal compounds can modulate T-helper cell (Th1/Th2/Th17) balance, reducing autoimmune activity while maintaining adequate defenses against pathogens [36]. Others act on innate

immune cells, such as macrophages and dendritic cells, to regulate the release of pro-inflammatory mediators[37]. This dual effect can help prevent both excessive inflammation and immunosuppression.

Hepatoprotection and Detoxification

Herbs may promote hepatocyte viability by:

- **Protecting Mitochondrial Function**: Maintaining ATP levels and preventing apoptosis[38].
- **Enhancing Detox Enzymes**: Inducing Phase II conjugation enzymes (e.g., glutathione S-transferase), thereby facilitating toxin clearance[39].
- **Stabilizing Hepatic Cell Membranes**: Reducing lipid peroxidation and promoting membrane fluidity[40].

FORMULATIONS AND DELIVERY METHODS

Traditional Preparations

Decoctions (long simmering of herbs in water) and teas remain popular in many cultures[41]. Fermented herbal products, such as certain Ayurvedic Asavas or Arishtas, may offer enhanced bioavailability and shelf-life due to microbial transformations [42].

Modern Dosage Forms

Standardization of herbal extracts into capsules, tablets, and syrups caters to clinical precision and patient compliance[43]. Moreover, emerging technologies like phytosomes and nanoencapsulation improve the solubility, stability, and targeted delivery of key phytochemicals[44]. This can be especially useful for compounds with low bioavailability (e.g.,curcumin).

Table 1: Modern Herbal Formulation Technologies and Their Benefits

Technology	Description	Benefits
Phytosomes	Phospholipid complexes	Improved stability
Nanoemulsions	Nano-scale droplets of active compounds	Improved stability & faster onset
Liposomes	Bilayer vesicles encapsulating constituents	Targeted delivery & reduced toxicity
Solid Dispersions	Incorporation of herbs into polymer matrices	Enhanced solubility of bioactives

Synergistic Blends

Polyherbal formulations leverage the principle of synergy where two or more herbs work in concert to provide a broader therapeutic spectrum[45]. This approach can address multiple pathophysiological targets in liver disease while minimizing the dosage of each individual component, potentially reducing adverse effects[46].

CLINICAL EVIDENCE AND APPLICATIONS

Evidence from Preclinical Studies

Animal models have provided valuable insights into how herbal formulas can modulate liver inflammation, reduce fibrosis, and enhance immune function [47]. Rodent studies on polyherbal formulations demonstrate improved liver enzyme profiles (ALT, AST) and reduced histological damage [48]. In vitro research further corroborates these findings by identifying molecular targets, such as p38 MAPK, NF-κB, and Nrf2 pathways[49].



Chart 1: Preclinical Study Workflow for Herbal Formulations

HUMAN CLINICAL TRIALS

Clinical trials evaluating herbal interventions in liver diseases vary in design, dosage, and outcome measures. Nonetheless, multiple randomized controlled trials (RCTs) and meta-analyses report positive effects [50,51]. Examples include:

- **NAFLD/NASH**: Some herbal blends significantly decreased hepatic steatosis and improved insulin resistance [52].
- **Viral Hepatitis**: Trials indicate reductions in viral load, normalization of liver enzymes, and better quality of life [53,54].
- **Autoimmune Liver Disorders**: Limited but promising data suggest immunomodulatory herbs can reduce flare-ups when used alongside immunosuppressants [55]. Despite encouraging evidence, heterogeneity in formulations and small sample sizes warrant caution in interpreting results[56]. Further large-scale, multicenter RCTs are essential for definitive conclusions[57].

SAFETY, EFFICACY, AND REGULATORY CONSIDERATIONS

Herbs are not inherently free of side effects. Possible adverse events include gastrointestinal disturbances, allergic reactions, and hepatic toxicity if the product is adulterated or misused[58,59]. Regulatory frameworks vary widely, but agencies like the World Health Organization (WHO) and national bodies (e.g., FDA in the United States, EMA in Europe) are increasingly emphasizing good manufacturing practices and pharmacovigilance for herbal supplements[60].

CHALLENGES AND LIMITATIONS

Standardization and Quality Control

One of the most critical obstacles in herbal medicine is the variability in active constituent levels due to differences in plant species, cultivation methods, and processing techniques[61]. Standardization of marker compounds is necessary to ensure batch-to-batch consistency and reproducibility in clinical outcomes[62].

Complexity of Multi-Herb Formulations

Polyherbal blends may contain dozens of bioactive chemicals, complicating the identification of primary active compounds and their mechanisms of action[63]. This complexity also poses challenges in designing well-controlled clinical trials, as the synergy among components is difficult to isolate[64].

Integration with Conventional Therapies

Many patients with chronic liver disease already take prescription medications such as antivirals, immunosuppressants, or antihypertensives. Herb–drug interactions can alter drug metabolism, leading to suboptimal therapeutic efficacy or increased toxicity[65]. Hence, a coordinated approach among hepatologists, pharmacists, and herbal specialists is essential[66].

FUTURE PERSPECTIVES

Innovations in Formulation Technology

Advancements in nanoformulations, liposomal encapsulation, and probiotic-based delivery vehicles may improve bioavailability and target-specific action of herbal compounds[67]. Such innovations pave the way for safer, more potent, and personalized therapies.

Omics-Based Research

Genomic, proteomic, and metabolomic studies can reveal patient-specific responses to herbal treatments, aiding in the development of personalized medicine[68]. The interplay between host genetics and the gut microbiome may significantly affect herb metabolism and therapeutic outcomes[69].

Bridging Traditional Knowledge and Modern Science

Incorporating centuries-old empirical wisdom with cutting-edge biomedical research can uncover new therapeutic targets and refine existing herbal formulations[70,71]. Collaborative efforts that include ethnobotanists, phytochemists, clinicians, and regulatory agencies are critical to establishing credible guidelines and protocols.

CONCLUSION

Herbal formulations hold promise as adjunctive or complementary therapies for supporting immune function in liver diseases. Their multifaceted mechanisms ranging from antioxidant and anti-inflammatory actions to immunomodulatory pathways address key aspects of hepatic pathology. Although preclinical and clinical evidence highlights beneficial outcomes, challenges persist in terms of standardization, herb–drug interactions, and the design of high-quality clinical trials. Continued advancements in formulation technologies and omics-based research are likely to enhance the efficacy and safety of these herbal treatments. By embracing evidence-based approaches and

fostering collaborative research, healthcare providers can harness the full potential of herbal formulations to optimize liver health and immune resilience.

REFERENCES

1. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014; 383(9930): 1749 - 1761.
2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 371(9615): 838 - 851.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline. Hepatology. 2012; 55(6): 2005 - 2023.
4. Liaskou E, Wilson DV, Oo YH. Innate immune cells in liver inflammation. Mediators Inflamm. 2012; 2012: 949157.
5. Chen P, Starkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis-induced intestinal inflammation activates TNFRI and mediates alcoholic liver disease in mice. Hepatology. 2015; 61(3): 883 - 894.
6. Bhutani KK, Jadhav AN, Tewari S. Natural products drug discovery research in India: status and appraisal. Indian J Exp Biol. 2010; 48(3): 199 - 207.
7. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005; 2(4): 465 - 473.
8. Calapai G. European legislation on herbal medicines: A look into the future. Drug Saf. 2008; 31(5): 428 - 431.
9. Williamson EM, Lorenc A, Booker A, Robinson N. The rise of traditional Chinese medicine and its materia medica: A comparison of the frequency and safety of materials and species used in Europe and China. J Ethnopharmacol. 2013; 149(2): 453 - 462.
10. Otsuki N, Hatanaka Y, Takami S, et al. Bioactive constituents of herbal medicines used for the treatment of hepatic disorders in traditional Chinese medicine: pharmacological actions and mechanisms of action. Pharmacol Ther. 2021; 218: 107676.
11. Butterweck V, Nahrstedt A, Evans FJ, et al. Monoamine oxidase A and B inhibitory flavonoids from Hypericum perforatum: structure-activity relationships. Planta Med. 2002; 68(7): 577 - 582.
12. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009; 27: 147 - 163.
13. Tacke F, Luedde T. Trafficking and function of myeloid cells in liver inflammation. Curr Pharm Des. 2012; 18(27): 3712 - 3718.
14. Gao B. Hepatoprotection by IL-22: a new therapeutic target for the treatment of hepatitis. Front Immunol. 2020; 11: 544.
15. Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016; 13(3): 267 - 276.
16. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med. 2008; 29(1-2): 9 - 16.
17. Wu G, Tian T, Pan Z, et al. Gut microbiota and NAFLD: Potential therapeutic targets. J Immunol Res. 2020; 2020: 8784971.
18. Zhu Q, Li N, Zhao X, et al. Hepatic health: new pharmacological strategies to combat liver diseases. Curr Pharm Des. 2018; 24(29): 3381 - 3386.
19. Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. J Hepatol. 2014; 60(6): 1310 - 1324.
20. Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoimmune hepatitis: standard treatment and new therapies. Semin Liver Dis. 2019; 39(2): 259 - 272.

21. Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol. 2019; 70(3): 531 - 544.
22. Suriawinata AA, Thung SN. Liver pathology: cirrhosis, hepatitis, and primary liver tumors. Update Diagn Pathol. 2020; 16(2): 383 - 396.
23. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Drug metabolism by CYP3A4 and CYP3A5 in microsomes and reconstituted systems. Biochem Pharmacol. 2012; 84(3): 374 - 383.
24. Pietta PG. Flavonoids as antioxidants. J Nat Prod. 2000; 63(7): 1035 - 1042.
25. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011; 17(18): 2288 - 2301.
26. Rios JL, Andújar I, Recio MC, Giner RM. Lanains and other terpenoids from Lamiaceae as anti-inflammatory agents: an update. Mini Rev Med Chem. 2013; 13(7): 937 - 950.
27. Tang Q, Huang W, Song XY, et al. Alkaloids with potential neuroprotective activities from nature resources. Curr Med Chem. 2019; 26(26): 4926 - 4945.
28. Tiwari A, Bajpai R, Singh V, Patni D. An update on Ayurvedic herb Kutki (Picrorhiza kurroa): from classical Ayurvedic knowledge to modern biological evidence. J Ethnopharmacol. 2019; 229: 225 - 236.
29. Shen JD, et al. Traditional Chinese Medicine in Liver Diseases: An Emerging Role in the Era of Precision Medicine. Phytomedicine. 2020; 79: 153359.
30. Liu C, Sun Y, Shen W. A standardized approach to evaluating and identifying high-quality herbal extracts. Chin Med. 2021; 16(1): 82.
31. Li S, Chen HY, Wu BH, et al. From herbalomic to mass spectrometry-based omics: current advances in analysis of medicinal plants. OMICS. 2015; 19(10): 601 - 610.
32. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014; 61(6): 1385 - 1396.
33. Joung H, Kim Y, Park S, Ko YG, Kim HN, Park YK. Improved antioxidant status is associated with attenuated inflammatory markers in overweight and obese adults. Nutr Res Pract. 2018; 12(5): 409 - 416.
34. Yu W, Qin X, Zhang Y, et al. Mechanisms of GSH in antiviral, anti-inflammatory, and immune responses. Free Radic Biol Med. 2022; 192: 226 - 236.
35. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017; 2: 17023.
36. Bae M, Cassilly CD, Liu X, et al. Extracellular electron transfer enhances the anti-inflammatory and immunomodulatory effects of probiotics. Cell. 2022; 185(25): 4640 - 4655.
37. Crispino P, et al. Herbal immunomodulators in liver diseases. Hepat Med. 2019; 11: 95 - 107.
38. Mukhopadhyay P, Horvath B, Rajesh M, et al. Mitochondrial dysfunction in hepatic injury and disease: from bench to bedside and beyond. Hepatology. 2012; 54(6): 2003 - 2015.
39. Xu S, et al. Comprehensive study of phase II metabolic enzymes in liver diseases. Arch Toxicol. 2018; 92(4): 1287 - 1303.
40. Alissa EM. New insights into lipids, inflammation and liver diseases: potential of omega-3 fatty acids. J Nutr Metab. 2021; 2021: 6676284.
41. Chen N, Li W, Yan F, et al. The use of herbal decoctions in Traditional Chinese Medicine for hepatic disorders. Phytother Res. 2021; 35(11): 5871 - 5890.
42. Parveen R, Baboota S, Ali J, Ahuja A. Fermented herbal preparations: A new horizon of nano-based natural dosage forms. Crit Rev Food Sci Nutr. 2019; 59(22): 3612 - 3620.
43. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014; 4: 177.

44. Makhija DT, Vavia PR. Nanoemulsions in healthcare: bridging the gap. Curr Opin Pharmacol. 2021; 60: 211 - 217.
45. Wagner H. Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia. 2011; 82(1): 34 - 37.
46. Yang W, et al. Understanding synergy in herbal medicine. J Ethnopharmacol. 2014; 154(3): 709 - 722.
47. Zhou YY, et al. Phytotherapy for alcoholic liver disease: from bench to bedside. World J Gastroenterol. 2019; 25(7): 871 - 881.
48. Ghaznavi H, et al. Effect of polyherbal formulation on liver fibrosis in experimental models. Biomed Pharmacother. 2020; 130: 110571.
49. Wang H, et al. Mechanistic insights into the synergy of multiple herbs in TCM: a case study on a polyherbal formulation for liver fibrosis. Pharmacol Res. 2020; 159: 104979.
50. Momeni A, et al. Herbal medicines for fatty liver disorders: a systematic review of randomized controlled trials. Clin Nutr ESPEN. 2019; 30: 10 - 17.
51. Zhu Y, et al. Efficacy and safety of herbal medicine in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. J Tradit Chin Med. 2021; 41(2): 244 - 254.
52. Ampasavate C, et al. Clinical benefits of a multi-herb formulation on NAFLD. J Med Food. 2021; 24(4): 405 - 412.
53. Song YN, et al. Efficacy of integrated Traditional Chinese Medicine and Western medicine for chronic hepatitis B: a systematic review of RCTs. Evid Based Complement Alternat Med. 2021; 2021: 6419948.
54. Samad N, et al. Role of herbal extracts in modulating hepatitis C virus infection: an overview. J Ethnopharmacol. 2017; 214: 10 - 20.
55. Zhu J, et al. Traditional Chinese herbal therapy in the management of autoimmune hepatitis. Medicine (Baltimore). 2021; 100(20): 25792.
56. Li T, et al. Significance of herbal medicine in controlling advanced liver diseases: A meta-analysis. Front Pharmacol. 2020; 11: 614461.
57. Hu Y, et al. Quality of randomized controlled trials on herbal therapy for chronic liver disease: a review. Chin Med. 2016; 11: 29.
58. Bunchorntavakul C, Reddy KR. Herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013; 37(1): 3 - 17.
59. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016; 17(1): 14.
60. EMEA. Guideline on the assessment of clinical safety and efficacy in the preparation of herbal medicinal products. London: European Medicines Agency; 2006.
61. Pan SY, et al. New perspectives on complementary and alternative medicine: an overview and alternative therapy. Altern Ther Health Med. 2012; 18(4): 20 - 36.
62. Kunle OF, Egharevba HO, Ahmadu PO. Standardization of herbal medicines. Int J Biodivers Conserv. 2012; 4(3): 101 - 112.
63. Ma B, et al. Multi-component synergy of herbal medicines: A perspective from systems pharmacology. Comput Struct Biotechnol J. 2019; 17: 1237 - 1247.
64. Yuan H, Ma Q, Ye L, Piao G. The Traditional Medicine and Modern Medicine from Natural Products. Molecules. 2016; 21(5): 559.
65. Fasinu PS, et al. Current state of herb–drug interaction research: a review of the data, challenges, and considerations for future studies. Drug Metab Dispos. 2012; 40(4) :694 - 701.

66. Mattos AA, et al. Interdisciplinary approach for patients with advanced chronic liver disease: a critical look at integrative medicine. Clin Liver Dis. 2021; 25(2): 447 - 463.
67. Yan K, et al. Nanotechnology strategies for herbal medicine-based therapy in liver diseases. Front Pharmacol. 2020; 11: 553701.
68. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013; 11(2): 110 - 120.
69. Li R, Wu Q, et al. Gut microbiota and herbal medicine: an emerging paradigm in immunomodulation. Evid Based Complement Alternat Med. 2021; 2021: 3334250.
70. Ji HF, Li XJ, Zhang HY. Natural products and drug discovery. EMBO Rep. 2009; 10(3): 194 - 200.
71. Heinrich M, Modarai M, Kortenkamp A. The challenges of integrating traditional medicines into modern medical and scientific practices. J Ethnopharmacol. 2020; 248: 112264.